Economy/Home · Economy

SK Bioscience Q3 Revenue Up 21.0%... Operating Loss of KRW 11.2 Billion as Deficit Narrows 42.1%

SK Bioscience reported quarterly results featuring both revenue growth and a narrower deficit, with pre-tax profit and net income returning to the black. According to a regulatory filing on the 5th, the company's third-quarter consolidated revenue came to 182.44 billion won, up 21.0% from 150.76 bil

Oseong Kwon
Staff Reporter
4 min read
SK Bioscience Q3 Revenue Up 21.0%... Operating Loss of KRW 11.2 Billion as Deficit Narrows 42.1%
CBC News

SK Bioscience reported quarterly results featuring both revenue growth and a narrower deficit, with pre-tax profit and net income returning to the black. According to a regulatory filing on the 5th, the company's third-quarter consolidated revenue came to 182.44 billion won, up 21.0% from 150.76 billion won a year earlier and up 17.2% from the previous quarter's 155.70 billion won. The Q3 operating loss was provisionally tallied at 11.21 billion won, a 42.1% reduction from the 19.37 billion won loss a year earlier and a 28.7% decrease from the previous quarter's 15.73 billion won loss. Profit from continuing operations before income tax expenses turned positive at 6.03 billion won, compared to losses of 15.57 billion won a year earlier and 16.43 billion won in the previous quarter. Net income was 12.08 billion won, down 43.0% from 21.08 billion won a year earlier, but marked a return to profit from the previous quarter's net loss of 14.08 billion won. Net income attributable to owners of the parent company was 10.53 billion won, down 57.0% from 24.47 billion won a year earlier and a turnaround from the previous quarter's net loss of 17.88 billion won. For the first three quarters of this year, cumulative revenue rose 8.5% year-on-year to 506.75 billion won from 467.18 billion won. The cumulative operating loss narrowed 0.6% to 71.49 billion won from 71.89 billion won, and the cumulative loss from continuing operations before income tax expenses fell 9.9% to 58.18 billion won. However, the cumulative net loss for the period stood at 38.23 billion won, a swing from a net profit of 230 million won a year earlier, and the net loss attributable to owners of the parent company was 40.68 billion won, reversing from a net profit of 537 million won. SK Bioscience stated that these results are provisional figures based on consolidated financial statements prepared under K-IFRS and may change depending on the results of the external auditor's accounting review.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.